echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Chengdu Biotechnology Institute has made important progress in palladium-catalyzed asymmetric carbonylation research

    Chengdu Biotechnology Institute has made important progress in palladium-catalyzed asymmetric carbonylation research

    • Last Update: 2022-11-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      

     Palladium-catalyzed carbonylation is an important reaction widely concerned by academia and industry, and has a wide range of applications in the construction of a variety of practical molecules, through the introduction of carbon monoxide (carbonylation process), bulk chemical raw materials, such as olefins, alkyl or aryl halide compounds, can be converted into high-value products
    such as aldehydes, alcohols and carboxylic acid derivatives.
    However, classical palladium-catalyzed (zero-valent/divalent palladium-catalyzed cycle) carbonylation still faces great challenges
    in achieving high yield, high chemical selectivity, high regional selectivity, and enantioselectivity.

    The team of researcher Liao Jian of the Drug Design and Synthesis Project Group of Chengdu Institute of Biology, Chinese Academy of Sciences has developed a new strategy
    for asymmetric amine carbonylation using chiral sulfoxide/palladium complex as catalyst and high-valent palladium catalytic pathway.
    Through this strategy, under mild conditions, the carbonylation reaction with high yield, excellent chemoselectivity, regional selectivity and enantioselectivity was achieved, and a series of shaftal chiral a-ketoamide/amide compounds with high optical purity were synthesized,
    which showed good IL-1β inhibitory activity and very low cytotoxicity.
    It is expected to be developed as a small molecule drug candidate for the treatment of gout
    .
    In addition, the mechanism
    of high-valent palladium-catalyzed carbonylation was analyzed from the perspective of experimental and theoretical calculation.
    The research results have laid an important research foundation
    for the application of high-valent palladium catalysis in carbonylation and other important directions.
    The study, "
    Enantioselective double carbonylation enabled by high-valent palladium catalysis," was published in the Journal of the American Chemical Society, doctoral student Han Jian is the first author, researcher Liao Jian and academician Wu Yundong of Peking University Shenzhen Research Institute (responsible for theoretical calculation) are co-corresponding authors
    .
    This research was supported
    by the National Natural Science Foundation of China (22171258 and 21933004).
     

      

     

    Synthesis process (Image courtesy of J.
    Am.
    Chem.
    Soc.
    )

     Original link

     China invention patent--"Class I biphenylamide compounds and preparation methods and applications thereof" application number: CN202211119980.
    8
     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.